CYTH

Cyclo Therapeutics (CYTH)

About Cyclo Therapeutics (CYTH)

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Details

Daily high

$0.75

Daily low

$0.68

Price at open

$0.71

52 Week High

$2.12

52 Week Low

$0.59

Market cap

20.4M

Dividend yield

0.00%

Volume

23,143

Avg. volume

44,769

P/E ratio

-.81

Cyclo Therapeutics News